Extension study of WT4869 for MDS

Extension Study of WT4869 in Patients with Myelodysplastic Syndromes (MDS)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222621

Enrollment

Registered

2014-10-06

Start date

2014-09-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myelodysplastic syndromes

Interventions

investigational material(s) Generic name etc : WT4869 INN of investigational material : - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who completed Phase I/II study

Exclusion criteria

Exclusion criteria: Patients with concomitant infections of Grade 3 or greater

Design outcomes

Primary

Measure	Time frame
safety efficacy To assess the safety and efficacy of long-term treatment with WT4869 Safety: adverse events, clinical laboratory test, vital sign, body weight, 12-led ECG Efficacy: hematologic improvement/treatment or cytogenetic response, time to AML, overall survival	—

Secondary

Measure	Time frame
efficacy Hematologic response and hematologic improvement (erythroid, platelet, or neutrophil)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026